CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Grail Publishes Presentation on Blood-Based Detection of Liver and Bile Duct Cancers

By Public Technologies
  • Grail published a medical research presentation evaluating targeted ctDNA methylation profiling for liver and biliary tract cancers.
  • The blood test detected cancer signals in 86-95% of samples from 657 patients across three phase 3 trials.
  • A research-grade classifier identified 99.2% of biliary tract cancers as adenocarcinoma-like; HCC classification accuracy reached 77.4-81.9%.
  • Confirmed HCC samples classified as adenocarcinoma-like had lower tumor methylation fractions, highlighting a need for further classifier refinement and validation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk